Birinyi Associates Inc. maintained its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,000 shares of the medical equipment provider’s stock at the end of the second quarter. Birinyi Associates Inc.’s holdings in Zimmer Biomet Holdings were worth $257,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ZBH. QCI Asset Management Inc. NY boosted its stake in Zimmer Biomet Holdings by 1.3% in the second quarter. QCI Asset Management Inc. NY now owns 129,881 shares of the medical equipment provider’s stock valued at $16,677,000 after buying an additional 1,670 shares during the period. Sage Capital Advisors llc acquired a new stake in Zimmer Biomet Holdings during the second quarter valued at approximately $2,304,000. Schulhoff & Co. Inc. boosted its stake in Zimmer Biomet Holdings by 6.3% in the second quarter. Schulhoff & Co. Inc. now owns 3,620 shares of the medical equipment provider’s stock valued at $464,000 after buying an additional 215 shares during the period. Neuberger Berman Group LLC boosted its stake in Zimmer Biomet Holdings by 16.4% in the second quarter. Neuberger Berman Group LLC now owns 1,480,467 shares of the medical equipment provider’s stock valued at $190,092,000 after buying an additional 208,881 shares during the period. Finally, Pacer Advisors Inc. boosted its stake in Zimmer Biomet Holdings by 8.3% in the second quarter. Pacer Advisors Inc. now owns 4,598 shares of the medical equipment provider’s stock valued at $590,000 after buying an additional 351 shares during the period. Institutional investors own 85.47% of the company’s stock.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 112.10 on Tuesday. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The company’s 50-day moving average price is $120.75 and its 200-day moving average price is $120.97. The company has a market capitalization of $22.67 billion, a P/E ratio of 31.93 and a beta of 1.20.

Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.95 billion. During the same quarter in the previous year, the company earned $2.02 earnings per share. The firm’s revenue for the quarter was up 1.1% on a year-over-year basis. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.85%. The ex-dividend date is Thursday, September 21st. Zimmer Biomet Holdings’s payout ratio is presently 27.59%.

ILLEGAL ACTIVITY NOTICE: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/29/zimmer-biomet-holdings-inc-zbh-position-held-by-birinyi-associates-inc.html.

Several analysts have commented on the company. Gabelli assumed coverage on Zimmer Biomet Holdings in a report on Thursday, August 24th. They issued a “buy” rating and a $142.00 price target for the company. Oppenheimer Holdings, Inc. set a $137.00 price target on Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Monday, August 14th. Zacks Investment Research cut Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 8th. BidaskClub cut Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, BMO Capital Markets boosted their target price on Zimmer Biomet Holdings from $136.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, July 28th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $136.75.

In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sang Yi sold 17,731 shares of the company’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is owned by corporate insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.